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11 Introduction
For any developed country, an increase in the proportion of the elderly entails an increase in per
capita health care expenditure. This is undoubtly true, given that individual health care expenditure
is an increasing function of age. But what is the magnitude of this eﬀect in comparison with other
drivers of health care expenditures?
In this paper, we use micro data to evaluate the respective eﬀects of demographic change, changes
in morbidity and changes in practices on the growth in health expenditure that occurred in France
between 1992 and 2000. The time span we consider for our retrospective analysis is rather limited.
However, a non-negligible ageing of the population is observed during that period, at a pace which
is representative of what is expected for the future.
The consequences of ageing is an issue addressed by numerous macro and micro-economic papers.
At the macro-economic level, the vast majority of studies ﬁnd that age structure has a small or non
signiﬁcant impact on health care expenditures, whereas GDP has a sizeable and highly signiﬁcant
impact [1–8]. At the individual level, micro-economic studies ﬁnd as well that the inﬂuence of age on
health care expenditure is signiﬁcantly reduced when proximity to death is taken into account [9–13]
. Recently, the OECD [14] provided retrospective decompositions of the growth in public health care
spending, together with projections for 2050. For the OECD countries taken as a whole, the age eﬀect
accounted for less than one tenth of the growth in health care expenditure observed between 1970
and 2002. As for projections, the authors underline that non-demographic factors, including changes
in technology, are the most important drivers in the projected increase. For the OECD countries,
the share of health expenditure in GDP is forecast to increase by 3.9 percentage points (from 5.7 %
in 2005 to 9.6 % in 2050), of which 0.7 percentage point only is attributable to demographic eﬀects.
Earlier projections of future health care expenditures simulated the impact of ageing simply
by applying demographic projections to the observed proﬁle of health expenditure by age group.
However, changes in health care expenditure level also depend on changes of this proﬁle over time
[15,16]. Graph 1 displays the proﬁles computed on our French database for years 1992 and 2000.
Age group 0 corresponds to people age 0-9, age group 10 to people age 10-19, and so on, until age
group 70, which is related to people age 70 and over. As expected, expenditures increase with age.
The main feature, however, is that a sizeable upward drift of the proﬁle is observed between 1992 and
2000. This drift may be related to changes in health status at a given age. It may also be linked to
2Graph 1: Average individual health care expenditures by age group, years 1992 and 2000
technological progress or more broadly to changes in practices, for a given age and a given morbidity.
Beyond the pure demographic eﬀect, the upward drift of the age proﬁle is likely to be the main
driver of health care expenditure growth. In addition, it is of major importance to identify the causes
of this drift, i.e. the respective impacts of technological progress and of changes in morbidity.
Trying to forecast how health status by age might evolve in the future is a rather hazardous enter-
prise. A plentiful literature has examined how increases in longevity could inﬂuence the population’s
health status. Various hypotheses have been considered, the two extreme ones being ”expansion of
morbidity” [17] and ”compression of morbidity” [18]. Several intermediate hypotheses can be con-
sidered, with mixed situations and transition regimes regarding potential changes in illnesses and
disability [19]. At the macroeconomic level, a rough assessment is in general built on the basis of
the projected increase in longevity. For instance, the ”healthy ageing” hypothesis comes down to
assuming that gains in longevity are gains in healthy years. At the microeconomic level, the Future
Elderly Model, a microsimulation model built by the Rand, uses estimated transition rates to simulate
changes in health status and deaths for Medicare enrollees [20,21].
Evaluating the eﬀects of technological progress or changes in behavior is not easier. Evans et
al. [22] show that projections performed in the 70’s or in the 80’s greatly overstate the number
3of acute hospital days actually observed in 2000, and underestimate the use of physicians’ service.
At the microeconomic level, available studies generally focus on a limited number of illnesses and
procedures, such as hip replacement or treatment for heart attack [23, 24]. The macroeconomic
projections performed by the OECD [14] allow for ”non-demographic” factors by simply assuming
that health care expenditures grow 1% per annum faster than income, an assumption in keeping with
the trends observed over the past two decades.
To sum up, identifying the factors that inﬂuence the age proﬁle of health care expenditures is
a diﬃcult undertaking, which deserves further investigation. The purpose of this paper is to add a
contribution to this open question by proposing an original microsimulation method for analysing
changes over time in the age proﬁle. This method makes it possible to separately identify changes
that are due to changes in morbidity on the one hand, and to changes in practices on the other.
As regards morbidity, we consider a vector of chronic illnesses and disability indicators and allow
for the changes in prevalence by age that are observed over time for each illness or disability level.
Our estimation enables us to compute the resulting impact of all these changes on expenditures by
age. On the whole, this provides an accurate assessment of the total impact of changes in morbidity
on expenditures.
Our microsimulation method captures changes in practices through changes in the coeﬃcients
which measure the inﬂuence of morbidity on health care use. This allows us to observe for each
given illness whether health care expenditure is higher in 2000 than 1992. We thus capture a much
broader phenomenon than technological progress. Our method makes it possible to embrace changes
in patients’ preferences and physicians’ behavior as well as the impact of technological progress. All
these components are to be considered in order to provide a convincing decomposition of health care
expenditure growth.
Our data is a representative sample of 3,441 and 5,003 French individuals observed in 1992 and
2000. We apply our microsimulation approach to identify the components of the drift observed
between 1992 and 2000 in the age proﬁle of health expenditures. Our results show that changes in
morbidity induce a downward drift of the health care expenditures proﬁle, whereas the drift due to
changes in practices is upward and sizeable.
Once we have evaluated the respective inﬂuences of changes in morbidity and changes in practices
at the microeconomic level, we apply our results to the age structure of the French population in order
4to compare the aggregate eﬀects of demographic change and proﬁle drifts for the period 1992-2000.
At this macroeconomic level, the rise in health care expenditures due to demographic change is very
small, in comparison with the eﬀects of changes in practices. For total expenditures, we ﬁnd that
the impact of changes in practices is 3.8 times larger than the rise in health care expenditures due
to change in the age structure of the population.
In comparison with studies focusing on time to death [9–11,13], our database presents the ad-
vantage of providing information about many morbidity indicators, in addition to death proximity
(”death risk”). Furthermore, rather than studying only hospital expenditures or aggregate individual
expenditures [9–11], our dataset allows us to study the diﬀerent components of individual health
care expenditures: home and oﬃce physician visits, pharmaceutical expenditures, and hospital ex-
penditures. Such a detailed analysis lets us account for the very diﬀerent nature of these expenditure
components. For example, pharmaceutical and hospital costs are much inﬂuenced by technological
progress, unlike physician visits.
The paper is organized as follows. The next section presents the microsimulation method. In
section 3, we present the sample and give some information about the French health care system.
Then, we carry out a descriptive analysis of the data. The results of our microeconometric estimates
and simulations are commented on in section 4. In section 5, we conclude by using our microsimulation
outcomes to compare the aggregate impacts of demographic eﬀects and changes in proﬁles at the
macro level.
2 The microsimulation method
Our empirical approach entails several steps: we ﬁrst specify and estimate a model explaining the
decision to consume health care and the level of expenditure, conditional on that decision; we run the
model separately on data for 1992 and 2000. Then, we use the estimated coeﬃcients to simulate coun-
terfactual average levels of participation and expenditure by age group: this allows us to disentangle
the eﬀects of changes in morbidity and changes in practices in the proﬁle drift observed between
1992 and 2000. Finally, we use the simulated expenditure proﬁles to identify, at the macroeconomic
level, the respective impacts on expenditure growth of demographic change, changes in morbidity,
and changes in practices for a given morbidity. These steps are followed separately for each type of
5service: inpatient, physicians and prescription drugs.
2.1 The model
We use a two-part model, ﬁrst explaining the decision to consume health care, then explaining the
level of health care expenditures for participants. Such models are particularly appropriate in the
econometric analysis of individual health care expenditures. Indeed, a non-negligible proportion of
people do not use health services at all during a given year (about 10%), this proportion being much
higher as regards hospital (about 90% of non-users). Our decision to consider Log-transformed ex-
penditures is explained below, while our decision to use a model assuming independence between
participation and level of expenditure is discussed in subsection 2.3.
Consider individual i belonging to age group j. Pij is the dichotomic variable for participation
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(2)
Equation (1) describes the decision to use health care services and equation (2) the level of con-
sumption.




2,ij) is deﬁned as an exponential function
of X′
2,ijδ. Indeed, the non-zero observations for health expenditures are highly skewed (the skewness
varies between 4.50 and 15.47 on our data, depending on the year and type of expenditure considered).
Taking the log transformation reduces the skewness to values between -0.26 and 0.01. In addition,
we used for C∗
ij a gamma distribution, which enables us to take heteroskedasticity into account. The
choice of a gamma distribution is based on the outcomes of Park tests that we performed following
the approach suggested by Manning and Mullahy [25].
X′
1,ij and X′
2,ij are the explanatory variables of the participation and consumption equations.
These regressors entail dummies aj and αj related to the age groups and morbidity indicators M′
ij. In
6addition, equations (1) and (2) include explanatory variables (variables W ′
ij or Z′
ij) relative to socio-
economic characteristics of the individual [26]. The potential list of morbidity indicators includes
disability, death risk, the number of illnesses, self-assessed health, and indicators for the following
illnesses : diabetes, chronic obstructive pulmonary disease and related diseases, ischemic heart disease,
hypertension, circulatory disease, conditions associated with lipid metabolism, depression, sleeping
disorder, cataract, and arthritis, arthropathy and/or back pain. The potential list of socio-economic
characteristics includes level of earnings, social and occupational group, education level, coverage
by a complementary insurance, gender, family size and matrimonial status. The list actually used
depends on the equation considered ((1) or (2)) and of the type of expenditure (ambulatory care,
pharmaceutical or hospital expenditure): it has been set by a careful selection process. Signiﬁcant
variables were selected for each type of expenditure and for each equation of the model; among
the selected variables, those whose exogeneity seemed questionable were tested (synthetic morbidity
indicators and complementary coverage) and only those that proved to be exogenous were selected
(see section 2.3).
The morbidity indicators we use are quite comprehensive: they provide a multidimensional de-
scription of every individual’s health status. Morbidity is the only factor explaining the increasing
pattern of the health care expenditure proﬁle: when controlling for morbidity level, we have found
that health expenditure is no longer increasing with age [27].
Recently, a great number of studies suggested that time to death was the main factor explaining
the shape of the proﬁle [9–11]. As a matter of fact, time to death could be interpreted as an indicator
of morbidity, whose exogeneity could be questioned [28]. Our database provides us a proxy of time to
death (the Death Risk indicator) and very detailed information about chronic illnesses and disability.
Thus, we capture health status with more accuracy than with taking time to death only. Furthermore,
we are able to test for the exogeneity of our indicators.
2.2 Predictions and microsimulations
We perform simulations on participation and consumption behavior.








with Φ(.) standing for the cdf of the standard normal distribution.
As concerns expenditures for health care users, the GLM speciﬁcation leads to a direct estimate
of the conditional expectancy of expenditures on the raw scale:
∧









The model is estimated separately for years 1992 and 2000 for each type of expenditures (consulta-









Since the computation of predictors (3) and (4) involve several non-linear functions, we cannot
exhibit additive eﬀects. We use instead an incremental approach. As concerns the decision to use
health care services (participation), we compute the predicted probability for the average patient of
each age group j. This is done for each expenditure component, i.e. physicians visits, drugs and
hospital.
For individual i belonging to age group j and observed in 1992, the predicted probability of using






















































We have chosen this approach instead of computing the average by age group of individual pre-
dicted probabilities. This empirical strategy allows us to simulate the eﬀects of changes in morbidity,
while we hold constant the other explanatory variables.
We focus on changes in morbidity and changes in practices, for a given morbidity. The eﬀect
























8The incremental eﬀect of changes in morbidity between 1992 and 2000 is assessed by replacing,
for each age group j, the average level of morbidity observed in 1992, M′92
.j by the average level of




















Finally, the incremental eﬀects of other changes in behavior and individual characteristics lead to



























We used expression (4) and followed the same principles to compute the predictions of the levels









.j . More precisely, the means by age group of the explanatory variables are computed only
on the subsamples of participants, when simulating the conditional expenditures.
The same simulations are computed for participation, consumption of health care users and
unconditional consumption. Taking the example of the consumption of health care users, one has :




.j gives the eﬀect of changes in practices for a
given morbidity.




.j gives the incremental eﬀect of changes in
morbidity (among the participants) between 1992 and 2000.




.j gives the incremental eﬀect of other
changes in behavior and individual characteristics between 1992 and 2000.
Broadly understood, changes in practices are measured by changes in the estimated parameters of
(1) or (2) between 1992 and 2000. These changes are linked to changes in patients’ or physicians’ be-
havior. They also result from technological progress, which induces the use of more costly innovative
drugs and procedures. It may concern as well the extension of innovative procedures and prevention
protocols to old ages. For example, the use of surgical treatment of cataract changed dramatically for
people age 75-84 in France: it rose from 40 % to 55 % between 1993 and 1998 [29]. Another example
is the increasing use of angioplasty for the treatment of Acute Myocardial Infarction. In France, the
9proportion of treatment by angioplasty rose from 9.6 % in 1993 to 22 % in 2001 for people age 75-
84 [30]. The increasing use of these procedures is observed in comparable developed countries [31]. It
stems, on the demand side, from changing preferences towards a better well-being of the elderly. On
the supply side, it derives from technological progress, which leads to better outcomes and improved
safety. This allows the extension of innovative procedures to older people. This might indeed raise
costs, but it also improves well-being for the elderly considerably.




β, which measure the inﬂuence of morbidity on participation rate and expenditures. What
we call ”other changes in behavior and individual characteristics between 1992 and 2000” can also
be interpreted as changes in practices. They depend on changes in the variables W and Z, as well








αj. For the sake of simplicity, we present the eﬀects of
changes in the age-speciﬁc constants in the last table only. These changes in age-speciﬁc constants
can be linked to changes in unobservable morbidity and to changes in practices for a given level of
morbidity.
Notice that our microsimulation method is in the spirit of the Oaxaca methodology [32]. It has
been recently extended to study income distribution in developing countries [33] and used to analyse
the process of technological progress diﬀusion within French hospitals [34].
2.3 Estimation methods
A typical feature of health expenditure data is that many individuals incur no health cost within
the period of observation. Such a conﬁguration requires speciﬁc estimation techniques. Many papers
addressed the issue of the choice between the sample-selection model (Heckit [35]) and the two-part
model [36–38]. Monte Carlo studies implemented by Manning, Duan and Rogers [38] show that the
two-part model may perform better than the sample selection model even when the latter is the true
model. Leung and Yu [37] have shown that the performances of the sample selection model depend
crucially on the degree of collinearity between the inverse Mill’s ratio and the explanatory variables
in the second step equation. When there is no collinearity, a t-test of the coeﬃcient of the inverse
Mill’s ratio can be used to choose between the two speciﬁcations. When there is collinearity, the
two-part model is more reliable because it performs better than the sample-selection model in terms
of mean-squared error.
10Our data is characterized by a high correlation between the inverse Mill’s ratio and the explanatory
variables of the second step equation: the correlation coeﬃcient lies between 0.85 and 0.87, depending
on the health expenditure component considered. We thus chose the two-part model. This model
presents another advantage: it permits the use of a generalized linear model estimator (GLM) to
estimate the level of consumption, conditional on participation. The GLM makes it possible to deal
rather easily with other typical features of health consumption data, such as skewness in the raw-
scale variable, heavy-tailed distributions and heteroscedastic errors. Indeed, it makes it possible (i)
to avoid the retransformation diﬃculties by specifying directly the expectancy of expenditure instead
of the Log of expenditure, (ii) to allow for heavy-tailed distributions and heteroscedastic errors by
considering Poisson or Gamma distributions for the dependent variable [25].
Some morbidity indicators may be non exogenous. Chronic diseases are likely to be exogenous:
they cannot be cured and their onset is independent from the amount of medical care provided.
But this is not the case for disability and synthetic indicators of health status, such as death risk,
self-assessed health and number of diseases. Coverage by a complementary insurance may also be
non exogenous, since it results partly from a decision of the individual. We have chosen to select only
exogenous regressors to avoid adding methodological diﬃculties to an already rather sophisticated
empirical approach. Exogeneity tests have thus been performed for the following variables: coverage
by a complementary insurance, death risk, self-assessed health, disability and number of diseases [27].
Thanks to the richness of our data, we were able to perform Hausman tests for each type of health
care consumption (consultations, pharmaceutical and hospital expenditures). This was possible for
year 2000 only. Instruments used were head of household status (working, unemployed, non-working,
the reference being retired), a dummy indicating whether the individual is a smoker, another dummy
indicating whether he/she receives minimum beneﬁt payment, height, BMI. Not enough instruments
were available for 1992, when the survey did not record enough information about socioeconomic
variables nor about individual characteristics and habits. Nevertheless, it seems to us legitimate to
assume that exogeneity checked for 2000 holds for 1992.
We used intrumental variables to build a Hausman speciﬁcation test for each of the three types of
health care consumption (detailed procedures are described in [27]). A Sargan test was used to check
the validity of the instruments used. In addition, we examined whether this test could be subject to
the weak instrument problem [39]. We found a large signiﬁcance of the partial correlation between
11instruments and morbidity indicators, with high statistics and levels of signiﬁcance lower than 10−3.
Sargan tests validated the instruments’ exogeneity. Coverage by a complementary insurance appear
to be exogenous for consultations and pharmaceutical expenditures (it is not a signiﬁcant regressor
for hospital). Exogeneity is rejected for disability as regards consultations expenditures and for death
risk as regards pharmaceutical expenditures.
3 Data
3.1 The dataset
We make use of a micro-economic data set concerning 3,441 insured French citizens for the year
1992 and 5,003 for the year 2000. This data set results from a survey (Sant´ e Protection Sociale)
conducted by IRDES (Institute for Research and Information in Health Economics, Paris) on a sub-
sample drawn from administrative data (Echantillon Permanent d’Assur´ es Sociaux) provided by the
French public health insurance, which records every health expenditure submitted to reimbursement
by subscribers.
The sample gives reliable information about each individual’s health care expenditures, the subscrip-
tion to a complementary insurance coverage, morbidity and socio-demographic characteristics such
as age, social and occupational group and net income. The sample is composed of people living in
regular households. Therefore, it does not provide an appropriate information about long-term care,
which is out of the scope of this paper. Between 1992 and 2000, the use of institutionalization has
remained stable. Thus it is not likely to aﬀect our results. Although of a reasonable size, our sample
is not large enough to record numerous observations for the individuals aged 80 and more. We thus
cannot consider separately an age group corresponding to the oldest old. We have deﬁned age groups
from 0 to 69 with ten-year intervals, and a last group for individuals age 70 and over.
Individual physician and pharmaceutical expenditures are directly observed by the public health
insurance. Hospital expenditures are evaluated at the individual level by the health insurance ad-
ministration on the basis of the individual’s recorded length of stay and of the average daily cost of
stay in the corresponding care unit.
In order to make health care expenditures comparable between years 1992 and 2000, we adjusted
the observed expenditures for inﬂation and converted all values to Euros. The price index [40] is
12speciﬁc to the type of expenditure of interest. Between 1992 and 2000, the computed price index of
physician consultations rose by 9.15%, reﬂecting changes in fee levels, which are mostly regulated.
The price index of ambulatory pharmaceutical expenditures rose by 2.04%. It does not reﬂect the
price of innovations, which are not included in this index. The price index of hospital expenditures
rose by 16.54%. Like the pharmaceutical expenditures price index, it does not include technological
progress. Indeed, the daily cost of stay in each care unit is computed on the basis of the use of
doctors’ and nurses’ work (duration and intensity of care), together with a combination of the index
of civil servants’ wages and price index of regular goods.
Therefore, we simply adjust for the general inﬂation rate. The growth of adjusted health care
expenditures we want to analyze is still inﬂuenced by the pace of technological progress, which we
are precisely interested in.
3.2 The French health care system
The French health insurance system is public and universal. About 99% of the population is covered,
without age restriction: coverage is continuous over the entire life span. It also grants unlimited
access to care, without frequency restrictions, at least for the period under study. Consultations for
ambulatory care are initiated by the patient. But the level of drug consumption is decided on by the
physician through prescriptions. In France, specialist consultations mostly take place in ambulatory
care and not within hospital. Until 2006, patients had free access to specialists. The public insurance
system covers almost 100 % of hospital care expenditures and 70% of expenditures for ambulatory
care. A large majority - 80% - of the population has complementary insurance. It may result from
a decision of the individual, but is more often provided by the employer. Complementary insurance
reimburses the remaining 30% of ambulatory care expenditures. Ambulatory care coverage includes
pharmaceutical expenditures. This contrasts strongly with other systems, such as Medicare in the
US or public coverage in many provinces of Canada. In 2000, Medicare in the US did not cover
medication when it was not prescribed in hospital. In France, the overall value of drug prescriptions
is growing rapidly because of the rising prices of innovations newly allowed on the market. On
the whole, between 1992 and 2000, total pharmaceutical expenditures increased by 59% in volume,
whereas the total number of physicians’ visits increased by 18% [40].
In France, physicians in the ambulatory care sector are mostly self-employed and paid on a fee-
for-services basis. Hospitals are public (2/3 of stays) or private (for proﬁt or not-for-proﬁt). Patient
13selection is forbidden in the public sector. The use of high tech innovative procedures mostly take
place in teaching hospitals, which are public. Until 2004, public hospitals and some private not-for-
proﬁt hospitals were regulated through a global budget system. Other private hospitals were paid on
a fee-for-service basis. For the period under study, there is no reason for rationing in access to care
for the elderly. Indeed, in addition to the fact that selection is not allowed in the public sector, the
global budget payment system does not provide incentives to reject patients with complications or
comorbidities. As concerns ambulatory care and hospital care in the private sector, the fee-for-service
scheme does not provide incentives for patient selection.
Thanks to their coverage, the French elderly do not face ﬁnancial constraints which could limit
their access to health care. In addition, since they have been well covered their whole lives, there is no
reason why health care expenditures should rise at a particular age. Such a rise could be observed in
the US, where people can delay care until they become eligible for Medicare at 65. Being continuous
over the lifetime, coverage in France is unlikely to inﬂuence the proﬁle of health expenditures by age
group.
3.3 Descriptive analysis
3,441 individuals are observed in 1992 and 5,003 in 2000. We chose not to remove outliers from the
data: removing the individuals who incurred the highest expenditures would jeopardize the repre-
sentativity of the sample, especially for hospital expenditures.
Individual expenditure is explained by the participation rate and by the conditional expenditure i.e.
expenditure observed for users. Graphs 2a-i show for each type of expenditure (physician visits,
medication and hospital expenditures) the age proﬁle of participation rate, conditional expenditure
and unconditional expenditure. The participation rates of physician visits and pharmaceutical ex-
penditures are high in 1992 and 2000 for all age groups (around 90%). The observed change in
the participation proﬁle has therefore a small impact on the unconditional expenditure. For these
expenditures, the conditional and unconditional expenditures proﬁles are very similar (see graphs
2e and 2f). This is not the same for hospital expenditures, for which the participation rate is quite
low (between 10% and 20%): changes in the participation proﬁle have a greater impact on the ﬁnal
proﬁle, which shows a sizeable drift between 1992 and 2000 for people age 50 and over. These features
show that ambulatory care and hospital care need separate analyses. It is an advantage of our data
14to make it possible to consider them separately.
For physician and pharmaceutical expenditures, the proﬁle (conditional and unconditional) is
clearly increasing with age. A noticeable upward drift of this proﬁle appears for people age 40 and
over between 1992 and 2000. The drift is spectacular and signiﬁcant (p < 0.0001) for pharmaceutical
expenditures, whereas it appears to be non signiﬁcant (p = 0.22) for physician consultations. To
check for the signiﬁcance of the drifts observed in the proﬁles, global signiﬁcance tests have been
carried out, as well as separate tests for each age group. Results are provided below graphs 2a-i : we
give the age groups for which a signiﬁcant drift is observed and the p-value of the global signiﬁcance
test.
15Graphs 2 : HCE participation and expenditures proﬁles, adjusted for inﬂation
(2a) Sign. drift (5%): 0, 10, 20, 30 (2b) Sign. drift (5%): 50 (2c) Sign. drift (5%): 50
p=0.0000 p=0.1201 p=0.2253
(2d) Sign. drift (5%): 0, 10, 20, 30, 40 (2e) Sign. drift (5%): 40, 60, 70 (2f) Sign. drift (5%): 10, 30, 40, 60, 70
p=0.0000 p=0.0000 p=0.0000
(2g) Sign. drift (5%): 20, 30, 40, 50, 60 (2h) Sign. drift (5%): none (2i) Sign. drift (5%): 60, 70
p=0.0000 p=0.5370 p=0.0057
16No general upward drift is clearly noticeable for hospital expenditures (conditional and uncondi-
tional) but a drift for people age 60 and over is observed (graph 2i). Participation rate for hospital
care has dramatically increased between 1992 and 2000, for all age groups (the drift is signiﬁcant
for each age group). This rise in participation explains the shape of the unconditional expenditures
proﬁles: the corresponding drift is signiﬁcant (p<0.0001, due to age groups 60 and 70 and over)
whereas the drift for conditional expenditures is not signiﬁcant (p = 0.54).
The hospital expenditure proﬁle is relatively ﬂat until the 50-59 age group, then becomes very
sloping. In a very enlightening descriptive analysis, Yang et al. [41] show that the age proﬁle of
Medicare expenditures (which are mainly determined by hospital costs) is strongly inﬂuenced by the
costs incurred by people who deceased within the year: when separating ”decedents”and ”survivors”,
the slope of the age proﬁle for survivors is far less steep. It is thus of major importance to check
whether the steep proﬁle we observe for the aged is not only due to people dying in hospital. Our data
allow us to know whether people observed in 2000 have survived until 2004. Graph 2j displayed below
shows hospital and pharmaceutical expenditure proﬁles for all individuals in 2000 and for survivors
only (still alive in 2004). The slope is less steep, but still noticeable for survivors. Therefore, the
shape of the hospital expenditure proﬁle is not only due to decedents. Interestingly, the steepening
of hospital expenditure proﬁle begins with age group 60, whereas the pharmaceutical proﬁle slope is
increasing from its very beginning (even for survivors).
4 Results
4.1 The estimates
The estimation of equations (1) and (2) reveals a strong inﬂuence of morbidity on participation
and conditional consumption (detailed results are provided for pharmaceutical expenditures in the
appendix, while the other results are available on request). Several morbidity indicators, the number
of diseases and the levels of disability and death risk have large positive impacts on the use of
health care services. To take an example, in 1992, a disability level equal to 3 (i.e. a situation
where the individual ”experiences diﬃculties but lives normally”) incurs an increase in conditional
pharmaceutical consumption of 42 %. When the disability level is equal to 4 or 5, the rise in the
conditional pharmaceutical consumption amounts to 77 % and 89 % (level 4 is the situation where the
individual ”must diminish his/her domestic or professional activity”, level 5 encompasses situations
17Graph 2j : Hospital and pharmaceutical expenditures (year 2000) of all vs. survivors until 2004
where the individual ”has diminished activity”, ”has no domestic autonomy”or ”is conﬁned to bed”).
The conditional pharmaceutical consumption is also strongly inﬂuenced by hypertension (+40 %),
diabetes (+ 48 %) trouble with lipid metabolism (+ 26 %) and depression (+ 37 %) (these ﬁgures are
given for the 1992 estimates). Participations to consultation and pharmaceutical consumption (see
table 3 in the appendix) are also signiﬁcantly inﬂuenced by our morbidity indicators. The conditional
consultation expenditure is positively inﬂuenced by depression (+27 %) and the number of diseases.
Turning to hospital expenditure, participation appears to be positively inﬂuenced by diabetes, death
risk and cataract, and conditional expenditure by the level of disability and hypertension (+37 %).
Otherwise, we ﬁnd that the absence of privately subscribed complementary coverage signiﬁcantly
reduces participation and consumption of ambulatory care. For example, in 1992, the drop amounts
to - 39% for conditional physician expenditures and to - 25% for conditional pharmaceutical expendi-
tures. On the other hand, complementary coverage has no signiﬁcant inﬂuence on the use of hospital
care. This is not surprising. Indeed, participation to hospital care does not result from an individ-
ual decision and the complementary insurance does not add any substantial coverage for hospital
care (see 3.2). In general, gender is not signiﬁcant for participation, but being a female increases
consultation and pharmaceutical expenditures by about 17 %. Gender is not signiﬁcant for hospital
18expenditures.
As stated above, changes in practices for a given morbidity are captured with changes in the
estimated coeﬃcients of morbidity indicators between 1992 and 2000. Our results show that for con-
ditional expenditures, most of the positive coeﬃcients estimated for the various morbidity indicators
are larger in 2000 than in 1992 (for pharmaceutical conditional expenditures - see table 2 in the
appendix - this is observed for hypertension, trouble with lipid metabolism, self-assessed health and
disability levels 2 to 5). The impact of changes in practices that we compute is the total eﬀect on
expenditure resulting from the changes that occured on the coeﬃcients of the morbidity indicators.
Not all the coeﬃcients of morbidity indicators do increase between 1992 and 2000. However, their to-
tal eﬀect might incur an increased level of expenditures. As shown below, our conjecture is validated
by the microsimulation results: for a given morbidity condition, expenditures are higher in 2000 than
in 1992.
The increasing shape of the age proﬁle of expenditure is entirely due to the fact that morbidity
is increasing with age [27]. However, it is not straightforward to assess the inﬂuence on expenditure
growth of changes in morbidity. Indeed, these changes are not uniform: improvements or deteriora-
tions can be observed, depending on the age group considered. This is illustrated by the following
graph, which represents the prevalence of diabetes per age group. It does not allow us to draw any
clear-cut conclusion about a general improvement nor deterioration of health status between 1992 and
2000, and hence about its consequences on expenditures. Indeed, the prevalence of diabetes decreases
below the age of 69, and increases for people aged 70 and more. Neither do the age proﬁles of our
various morbidity indicators highlight a clear-cut change of prevalence or health status in general.
Our simulation method enables us to evaluate, for all the morbidity and disability indicators taken
as a whole, the total eﬀect of all these various changes.
19To sum up, our microsimulation method makes it possible to evaluate the total eﬀects of multi-
dimensional changes, both in practices and in morbidity.
4.2 Microsimulations: identifying the impacts of changes in practices
and morbidity
Our simulations led to the calculation of average probability of participation and average conditional





















conditional expenditures were computed. At each step of simulation, unconditional expenditure C is
computed as the product π ∗ (C|P). The resulting proﬁles by age group are displayed in graphs 3a
and 3b for unconditional pharmaceutical and hospital expenditures. For each variable of interest, the
drift between the proﬁle of 1992 (proﬁle 1) and the proﬁle of 2000 (proﬁle 4) is split into 3 incremental
eﬀects : (i) the transition from proﬁle 1 to proﬁle 2 gives the eﬀect of changes in practices for a given
observable level of morbidity ; (ii) the transition from proﬁle 2 to proﬁle 3 gives the eﬀect of changes
in morbidity ; (iii) the transition from proﬁle 3 to proﬁle 4 gives the eﬀect of other changes in behavior
and individual characteristics. Ambulatory care (physician and pharmaceutical expenditures) and
hospital expenditures show fairly diﬀerent results, which are worth treating separately.
Our simulations led to the construction of 9 graphs, corresponding to participation, conditional
and unconditional expenditures for the three types of expenditures. To simplify the presentation,
we provide only two graphs relative to the pharmaceutical and hospital unconditional expenditures.
Indeed changes in the age proﬁle of the physician expenditures prove to be non signiﬁcant between
1992 and 2000 (see 3.3). The reader interested by detailed results about simulations for participation
20and unconditional expenditures for drugs and hospital can refer to Dormont & Huber [27].
4.2.1 Ambulatory care
For ambulatory care, the bulk of changes is essentially due to changes in expenditures conditional
on participation and not to changes in participation. The latter have a very small inﬂuence because
participation to ambulatory care is already high in 1992 and changes that occurred in 2000 are limited
(see section 3.3).
The tremendous rise in pharmaceutical expenditures is clearly observable on graph 3a. Our
simulations show that this large upward drift is almost entirely due to changes in practices for a
given level of morbidity (proﬁle 1 to 2). It means that for the level of morbidity they experienced in
1992, individuals would have spent more in 2000 than what they actually spent in 1992, whatever
their age. Thus, changes in practices induce an increase in health care expenditures, for a given level
of morbidity.
The changes in morbidity induce a downward drift (proﬁle 2 to 3) for all age groups (except 70 +),
which partly compensates the upward drift due to changes in practices. This downward drift means
that changes in morbidity that occurred between 1992 and 2000 induced a decrease in health care
expenditures at every age below 70, all other things being equal as regards practices. More thorough
investigation would be needed in order to assess that health is indeed improving. What can be said
however is that changes in health conditions have retrospectively led to savings.
The changes that occured for pharmaceutical expenditures are spectacular, by far much larger
than what is observed for physician expenditures. Notice that, at the macroeconomic level, drugs are
responsible for the bulk of the growth in total health care expenditures: they account for one fourth
of total health care expenditures and their growth rate is more than twice as large as for physicians
and hospital [27].
Our results show that for drugs the drift in the age proﬁle is entirely due to changes in practices,
for a given level of morbidity. It is not due to changes in the behavior of the elderly on the demand
side. Indeed, changes in participation have a negligible inﬂuence and the level of consumption derives
from prescriptions (it is the doctor’s decision). There is a large innovation component on the supply
side: changes are likely to be connected with the supply of new products on the health care market.
21Graph 3a : Simulated unconditional pharmaceutical expenditures
4.2.2 Hospital
For hospital unconditional expenditures, we ﬁnd again the positive eﬀect of changes in practices for
a given morbidity (proﬁle 1 to 2) as well as the negative eﬀect of changes in morbidity (proﬁle 2 to
3). These changes are observed only for people age 40 and over (graph 3b). The drift observed for
the two last age groups is due to the combined eﬀects of changes in practices and ”other changes”.
What is observed for hospital care contrasts strongly with ambulatory care, in the sense that
changes in the unconditional expenditure are mainly due to a drift in the participation proﬁle. The
drift in participation rates is observed for every age group and is increasing with age (see graph 2g).
Our simulation shows that this upward drift is due ﬁrstly to the ”other changes” and secondly to
changes in practices for a given level of morbidity, along with a slight downward drift due to the
changes in morbidity.
22Graph 3b : Simulated unconditional hospital expenditures
5 Conclusion: assessing the pure demographic eﬀect at the
macro level
The microsimulations performed above have enabled us to identify the components of the proﬁle
drifts observed between 1992 and 2000, i.e. what is due to changes in practices and what is due to
changes in morbidity. Our simulated proﬁles can be applied to the structure by age of the French
population. This leads to an assessment of the relative eﬀects of demographic change and proﬁle
drifts for the period 1992-2000 at the aggregate level.
Results are provided in table 1. The total demographic eﬀect is computed assuming that the 1992
age proﬁle of expenditures is held constant, and that only the structure and size of the population
changed over time. The other eﬀects are then computed by using the diﬀerent simulated proﬁles. A
bootstrap analysis has been performed to assess the signiﬁcance of these results (bootstrap by pairs,
800 replications).
The rise in health care expenditures due to demographic change appears to be very small in
comparison with the eﬀects of changes in practices. For total expenditures, we ﬁnd that the impact
of changes in practices is equal to +12.9%, which is 3.8 times more than the rise in health care
23expenditures due to changes in the age structure of the population (+3.4%).
The aggregate eﬀect of changes in morbidity appears to be negative for each type of health
expenditure, indicating health improvements of individuals for a given age between 1992 and 2000.
For total expenditure, this negative eﬀect of changes in morbidity (-9.7 %) more than oﬀsets the
positive shock due to changes in the age structure of the population (+3.4 %). This is also true for
pharmaceutical and hospital expenditures.
Variation 1992-2000 (%) Physicians Pharmac. Hospital Total
Total demographic change 5,05 7,63 6,37 6,35
of which :
part of structural change 2,10 4,61 3,38 3,36
part of growing size of population 2,95 3,02 2,99 2,99
Changes in practices for a given morbidity -15,09 52,24 7,06 12,87
Changes in morbidity -1,23 -9,24 -14,61 -9,74
Changes in age dummies 28,63 14,11 -26,25 -1,55
Other changes -2,80 2,53 95,51 45,95
Total variation 1992-2000 (%) 14,57 67,27 68,08 53,89
Table 1 : Simulations at the macro level
Our results show that ageing explains only a small part of the rise in health care expenditures.
Changes in practices for a given morbidity are by far a more important driver. For ambulatory care,
changes in practices are not linked to changes in participation behavior but to changes in conditional
consumption. The drift due to changes in practices is spectacular for pharmaceutical expenditures,
suggesting a large innovation component. These results reveal that the drifts we observe are not due
to demand side changes in behavior.
We have considered a separate speciﬁcation for participation. This allows us to isolate changes
that can be due to patients’ initiative, whose magnitude proved to be negligible.
24Our data allow us to split health care expenditures into three components. Since we have separate
information on pharmaceutical expenditures, we are able to show that the upward drift in drug
consumption is mainly due to the supply side, i.e. to technological progress. Our database also has
the great advantage of providing detailed information about morbidity, while numerous papers of the
literature devoted to ageing are based on rather poor information about morbidity, often reduced to
a single indicator, i.e. time to death.
We set up an original microsimulation method to exploit the richness of our multidimensional
information about morbidity. This allows us : (i) to provide empirical evidence of global health
improvement (ii) to evaluate the savings due to changes in morbidity. Health care expenditures
are often conceived of as a burden and it is indeed very diﬃcult to measure their beneﬁts. Our
ﬁndings give evidence of health improvements. These results deserve further investigation: given the
size of our sample, the number of observations is rather small as regards people age 80 and over.
Implementing the same method on larger samples should give a better assessment of changes that
aﬀect morbidity for this age group.
Our microsimulation method makes it possible to identify the diﬀerent components of the growth
in health care expenditures. If this methodology were applied to data on other countries, it could
be used to measure the eﬀects of various forms of regulation of health care systems on expenditure
growth and access to care at diﬀerent ages.
In the case of France, we have shown that changes in practices appear to be the main driver in
the increase in expenditures. It is possible that technological progress is oriented towards the elderly
more than other age groups. In that case, the impact of changes in practices would increase with age.
Due to our data limitations, we were not able to estimate slopes speciﬁc to each age group in order
to study this question. Further investigation with larger samples will allow us to study the pattern
of technological progress diﬀusion more thoroughly.
256 Appendix: pharmaceutical expenditures estimates
Table 2 - GLM Consumption Equation : Pharmaceutical expenditures, 1992 and 2000
1992 (Obs: 2745) 2000 (Obs: 4307)
Var Coef. Std. Err. P>z Coef. Std. Err. P>z
age 0-9 5.829 0.170 0.000 5.995 0.311 0.000
age 10-19 5.594 0.189 0.000 5.970 0.341 0.000
age 20-29 5.833 0.186 0.000 5.948 0.327 0.000
age 30-39 5.814 0.188 0.000 5.924 0.328 0.000
age 40-49 5.749 0.183 0.000 5.980 0.324 0.000
age 50-59 5.843 0.181 0.000 5.904 0.326 0.000
age 60-69 5.927 0.183 0.000 5.888 0.331 0.000
age 70+ 5.955 0.191 0.000 6.010 0.333 0.000
female 0.178 0.039 0.000 0.237 0.070 0.001
school: never - - - - - -
school: primary -0.298 0.089 0.001 -0.341 0.139 0.014
school: junior high -0.171 0.101 0.089 -0.240 0.162 0.138
school: high school -0.233 0.110 0.034 -0.385 0.174 0.027
school: higher educ -0.276 0.115 0.017 -0.301 0.175 0.085
household size -0.032 0.017 0.057 -0.037 0.030 0.215
diabetes 0.481 0.113 0.000 0.206 0.221 0.351
hypertension 0.401 0.071 0.000 0.528 0.123 0.000
lipid 0.259 0.089 0.003 0.409 0.149 0.006
depression 0.373 0.083 0.000 0.025 0.157 0.875
arthro-dorso -0.100 0.060 0.095 -0.448 0.101 0.000
nb diseases 0.062 0.012 0.000 0.047 0.022 0.032
Self-Assessed Health -0.129 0.014 0.000 -0.121 0.027 0.000
disab 0 - - - - - -
disab 1 -0.014 0.075 0.856 0.024 0.126 0.851
disab 2 0.203 0.084 0.016 0.415 0.121 0.001
disab 3 0.418 0.092 0.000 1.135 0.143 0.000
disab 4 0.768 0.111 0.000 1.655 0.182 0.000
disab 5 0.886 0.161 0.000 1.390 0.272 0.000
No compl cov -0.250 0.065 0.000 -0.035 0.116 0.760
Test of global signiﬁcancy of the model: p < 0.0000 for years 1992 and 2000.
26Table 3 - Probit Participation Equation : Pharmaceutical expenditures, 1992 and 2000
1992 (Obs: 3441) 2000 (Obs: 5003)
Var Coef. Std. Err. P>z Coef. Std. Err. P>z
age 0-9 2.304 0.273 0.000 2.459 0.260 0.000
age 10-19 1.829 0.287 0.000 1.934 0.268 0.000
age 20-29 1.509 0.263 0.000 1.595 0.249 0.000
age 30-39 1.459 0.256 0.000 1.647 0.242 0.000
age 40-49 1.368 0.253 0.000 1.388 0.239 0.000
age 50-59 1.367 0.254 0.000 1.197 0.239 0.000
age 60-69 1.494 0.264 0.000 1.452 0.247 0.000
age 70+ 1.620 0.297 0.000 1.788 0.279 0.000
diabetes 0.560 0.281 0.046 0.205 0.245 0.403
hypertension 0.442 0.143 0.002 0.422 0.128 0.001
lipid 0.596 0.219 0.006 0.344 0.167 0.039
arthro-dorso 0.264 0.098 0.007 0.133 0.075 0.075
nb diseases 0.039 0.016 0.018 0.073 0.016 0.000
Self-Assessed Health -0.039 0.020 0.055 -0.043 0.020 0.032
female 0.099 0.053 0.061 0.160 0.048 0.001
soc: farmers -0.070 0.241 0.772 -0.068 0.194 0.725
soc: indep. 0.108 0.123 0.379 -0.364 0.098 0.000
soc: intell. 0.003 0.100 0.977 0.001 0.075 0.992
soc: interm. 0.290 0.072 0.000 0.071 0.071 0.318
soc: clerks 0.136 0.082 0.096 0.012 0.079 0.881
soc: qual. - - - - - -
soc: non-qual. 0.174 0.096 0.070 0.018 0.090 0.842
school: never - - - - - -
school: primary -0.305 0.131 0.020 -0.353 0.119 0.003
school: junior high -0.136 0.143 0.343 -0.169 0.128 0.185
school: high school -0.252 0.155 0.104 -0.114 0.137 0.406
school: higher educ -0.448 0.162 0.006 -0.438 0.138 0.001
matrim: married - - - - - -
matrim: divorced 0.105 0.185 0.570 0.095 0.137 0.488
matrim: widow -0.007 0.200 0.973 -0.090 0.184 0.625
matrim: single -0.417 0.093 0.000 -0.409 0.083 0.000
Household size -0.100 0.021 0.000 -0.034 0.020 0.083
No compl cov -0.403 0.076 0.000 -0.359 0.071 0.000
Test of global signiﬁcancy of the model: p < 0.0000 for years 1992 and 2000.
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